Doctors test if vaginal estrogen is safe for breast cancer survivors
NCT ID NCT00984399
Summary
This study checked if a low-dose vaginal estrogen tablet (Vagifem) is safe for breast cancer survivors taking aromatase inhibitor medications. Researchers measured whether estrogen from the vaginal tablet gets absorbed into the bloodstream, which could potentially affect cancer risk. The study involved 31 postmenopausal women with breast cancer who were experiencing vaginal dryness, a common side effect of treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center@Phelps Memorial Hospital
Sleepy Hollow, New York, United States
-
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States
Conditions
Explore the condition pages connected to this study.